

The Editors welcome topical correspondence from readers relating to articles published in the Journal. Letters should be submitted electronically via the BJS submission site ([mc.manuscriptcentral.com/bjs](http://mc.manuscriptcentral.com/bjs)). All correspondence will be reviewed and, if approved, appear in the Journal. Correspondence must be no more than 300 words in length.

# Comment on: Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease

## Editor

Kirkham *et al.*<sup>1</sup> concluded in their review of the current evidence for magnetic sphincter augmentation (MSA) that it is 'being used despite a lack of robust evidence for its effectiveness'. We disagree.




Their study was designed to summarize and appraise the reporting of studies of MSA in relation to the Idea, Development, Exploration, Assessment, Long-term Study Framework for Devices (IDEAL-D), which was published after MSA was introduced and not to analyse outcomes. This requires a formal meta-analysis of the MSA evidence base which currently includes cohort studies, larger safety cohorts, a device registry and an RCT showing efficacy over proton pump inhibitor therapy<sup>2</sup>. Indeed, the majority of IDEAL-D has been followed during the introduction of MSA.

A recent meta-analysis compared MSA with fundoplication and concluded that they achieved equivalent symptom and

acid reflux control but that MSA caused less gas bloat. Clearly, an RCT comparing MSA with fundoplication is desirable and would make an important contribution to the evidence base for MSA<sup>3</sup>. Sadly, an application to the MRC in 2012 for such a study was declined.

However, the safety of MSA has been established from recent large registry studies of 1000 and nearly 10 000 patients, reporting erosion rates of 0.1 and 0.3 per cent<sup>4,5</sup>.

Imperfect reporting of other outcomes does not discount these data. A fair and comprehensive review of the literature suggests that MSA is both safe and effective, notwithstanding the need for an RCT to compare the efficacy of MSA *versus* standard fundoplication to add to the existing 'real-world' evidence.

L. Bonavina<sup>1</sup> , N. Boyle<sup>4</sup> ,  
C. Dunn<sup>2</sup>, T. Horbach<sup>6</sup>,  
T. B. Knowles<sup>3</sup>, J. C. Lipham<sup>2</sup>,  
B. E. Louie<sup>4</sup>, S. Markar<sup>5</sup> ,  
S. F. Schppmann<sup>7</sup> and J. Zehetner<sup>8</sup>  
<sup>1</sup>Department of Surgery, University of Milan Medical School, Milan, Italy,  
<sup>2</sup>Division of Upper GI and General Surgery, Department of Surgery, Keck Medical Center of USC, University of Southern California, Los Angeles, California and <sup>3</sup>Swedish Digestive Health Institute, Division of Thoracic Surgery, Swedish Medical Center, Seattle, Washington, USA, <sup>4</sup>London Reflux Centre, Lister Hospital, and <sup>5</sup>Department of Surgery and Cancer, Imperial College, London, UK, <sup>6</sup>General and Abdominal Surgery, Schoen Clinic, Nürnberg Fürth,

Germany, <sup>7</sup>Medical University of Vienna, Austria and <sup>8</sup>Hirslanden, Bern, Switzerland

DOI: 10.1002/bjs.11567

- 1 Kirkham EN, Main BG, Jones KJB, Blazeby JM, Blencowe NS. Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease. *Br J Surg* 2020; **107**: 44–55.
- 2 Bell R, Lipham J, Louie B, Williams V, Luketich J, Hill M *et al.* Laparoscopic magnetic sphincter augmentation *versus* double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. *Gastrointest Endosc* 2019; **89**: 14–22.e1.
- 3 Guidozzi N, Wiggins T, Ahmed RA, Hanna GB, Markar SR. Laparoscopic magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: systematic review and pooled analysis. *Dis Esophagus* 2019; **32**: doz31.
- 4 Lipham JC, Taiganides PA, Louie BE, Ganz RA, DeMeester TR. Safety analysis of first 1000 patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease. *Dis Esophagus* 2015; **28**: 305–311.
- 5 Alicuben ET, Bell RCW, Jobe BA, Buckley FP 3rd, Daniel Smith C, Graybeal CJ, Lipham JC. Worldwide experience with erosion of the magnetic sphincter augmentation device. *J Gastrointest Surg* 2018; **22**: 1442–1447.